Pazopanib Dosing
The standard dose of pazopanib is 800 mg orally once daily, taken on an empty stomach (at least 1 hour before or 2 hours after a meal), with tablets swallowed whole and not crushed. 1
Standard Dosing Regimen
- Dose: 800 mg (four 200 mg tablets) once daily
- Administration: Without food (≥1 hour before or ≥2 hours after meals)
- Duration: Continue until disease progression or unacceptable toxicity
- Important: Swallow tablets whole—do not crush (crushing increases absorption rate and systemic exposure)
- Missed dose: Skip if <12 hours until next scheduled dose 1
Dose Reductions for Toxicity
The FDA label provides different dose reduction schedules depending on indication 1:
For Renal Cell Carcinoma:
- First reduction: 400 mg once daily
- Second reduction: 200 mg once daily
- Permanently discontinue if unable to tolerate 200 mg daily
For Soft Tissue Sarcoma:
- First reduction: 600 mg once daily
- Second reduction: 400 mg once daily
- Permanently discontinue if unable to tolerate 400 mg daily
Hepatic Impairment Dosing
Hepatotoxicity is the most critical concern with pazopanib, carrying an FDA black box warning. 1
Baseline Hepatic Impairment:
- Mild impairment: Reduce to 200 mg once daily
- Moderate impairment: Use is not recommended
- Severe impairment: Contraindicated
On-Treatment Hepatotoxicity Management:
ALT 3-8× ULN (isolated): Continue treatment with weekly liver function monitoring until return to Grade 1 or baseline
ALT >8× ULN (isolated):
- Withhold until improvement to Grade 1/baseline
- If resuming, use maximum 400 mg once daily with weekly liver tests for 8 weeks
- Permanently discontinue if ALT >3× ULN recurs despite dose reduction
ALT >3× ULN + bilirubin >2× ULN: Permanently discontinue immediately 1
Other Critical Dose Modifications
Permanently discontinue for:
- Arterial thromboembolic events (any grade)
- Thrombotic microangiopathy (any grade)
- Gastrointestinal perforation (any grade)
- Interstitial lung disease/pneumonitis (any grade)
- Posterior reversible encephalopathy syndrome (any grade)
- Grade 4 hemorrhage, venous thromboembolism, or cardiac dysfunction 1
Hypertension management:
- Grade 2-3: Reduce dose and optimize antihypertensive therapy
- Permanently discontinue if Grade 3 persists despite dose reduction and antihypertensives
- Grade 4 or hypertensive crisis: Permanently discontinue 1
Drug Interactions Requiring Dose Adjustment
Strong CYP3A4 inhibitors (e.g., ketoconazole): Reduce pazopanib to 400 mg once daily 2
Avoid concomitant use with:
- Strong CYP3A4 inducers (may decrease pazopanib levels)
- Antacids/PPIs/H2RAs (reduce pazopanib absorption due to pH-dependent solubility) 3
Clinical Context from Guidelines
Pazopanib is recommended as:
- First-line option for advanced clear cell RCC (Category 1) 4, 5
- Second-line option after prior therapy in RCC (Category 2A) 4, 6
- Second-line option for advanced soft tissue sarcoma after chemotherapy 7, 8
- Option for specific histologies: angiosarcoma, vascular sarcomas, extraskeletal myxoid chondrosarcoma, solitary fibrous tumor 7
Emerging Evidence on Dose Optimization
Recent research suggests that lower starting doses (600 mg or even 400 mg daily) may reduce toxicity while maintaining efficacy, particularly when guided by therapeutic drug monitoring targeting trough concentrations (Cmin) of 20-34 mg/L 9, 10, 11. However, the FDA-approved standard remains 800 mg daily, and dose individualization should be based on toxicity monitoring per the label 1.
Common pitfall: Approximately 60% of patients require dose reductions due to toxicity in real-world practice 9. Monitor liver function tests before initiation and regularly during treatment—hepatotoxicity can be severe and fatal.